Search results for "Molecular target"

showing 10 items of 187 documents

How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?

2014

Abstract: Since a chance for cure was found out in metastatic colorectal cancer (mCRC) patients undergoing a resection of liver and lung metastases, high tumor shrinkage by chemotherapy regimens and their combination with targeted agents have been addressed in potentially resectable mCRC. However, most mCRC patients cannot reach this opportunity because of tumor burden or metastatic sites. For these patients a salvage systemic therapy could be offered to prolong survival. To date, a huge number of clinical trials provided some evidences for the achievement of this goal. A lot of chemotherapeutic regimens in combination with biological therapies are now available. We tried to propose a simpl…

Oncologymedicine.medical_specialtyLung NeoplasmsColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistrySalvage treatmentTumor burdenalgorithm chemotherapy metastatic colorectal cancer salvage treatment target therapySystemic therapyResectionInternal medicineDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsmedicineHepatectomyHumansMolecular Targeted TherapyPneumonectomyBiologyPharmacologySalvage TherapyChemotherapybusiness.industryPatient SelectionTumor shrinkageLiver NeoplasmsMetastasectomymedicine.diseasedigestive system diseasesNeoadjuvant TherapyClinical trialTreatment OutcomeChemotherapy AdjuvantCritical PathwaysHuman medicinebusinessColorectal NeoplasmsEngineering sciences. TechnologyAlgorithms
researchProduct

Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?

2014

Abstract: In the past decade, the advent of targeted therapy led to a silent revolution in the war against lung cancer and a significant evolution on the concept of Phase I clinical trials design. Thanks to the specificity of their target, the new drugs have radically changed NSCLC treatment, leading to the development of personalized strategies. The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development, characterized by modern, biomarker-driven, early clinical trial design and shorte…

Oncologymedicine.medical_specialtyPathologyLung NeoplasmsPyridinesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryEML4-ALKCeritinibNSCLCTargeted therapyPanacea (medicine)CrizotinibCarcinoma Non-Small-Cell LungInternal medicineDrug DiscoveryHumansMedicineAnaplastic Lymphoma KinaseMolecular Targeted TherapySulfonesPrecision MedicineLung cancerDrug ApprovalProtein Kinase InhibitorsGene RearrangementPharmacologyCeritinib; Crizotinib; EML4-ALK; NSCLCClinical Trials Phase I as TopicCrizotinibCeritinibbusiness.industryPharmacology. TherapyClinical study designReceptor Protein-Tyrosine Kinasesmedicine.diseaseCeritinib Crizotinib EML4-ALK NSCLCClinical trialPyrimidinesDrug DesignPyrazolesMolecular MedicineAccelerated approvalbusinessmedicine.drugExpert Opinion on Therapeutic Targets
researchProduct

Current questions for the treatment of advanced gastric cancer.

2013

Abstract Background Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in advanced gastric cancer. Material and methods Seven questions of special clinical interest have been formulated previously to the literature review. With the aim of answering each of these questions, a specific search of the relevant trials and meta-analyses published or communicated from 1990 to date was performed. Results Patients treated with CT have a survival benef…

Oncologymedicine.medical_specialtymedicine.medical_treatmentAntibodies Monoclonal HumanizedTargeted therapyTrastuzumabStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyRandomized Controlled Trials as TopicPerformance statusbusiness.industryCancerGeneral MedicineTrastuzumabmedicine.diseaseSurgeryOxaliplatinIrinotecanRegimenOncologyDocetaxelbusinessmedicine.drugCancer treatment reviews
researchProduct

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

2015

AbstractThe ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its receptor members is frequently deregulated in many types of solid tumors. Various drugs targeting these receptors have been approved for cancer treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies. However, in a number of cases, the tumor relapses or progresses thus suggesting that not all cancer cells have been targeted. One possibility is that a subset of cells capable of regenerating the tumor, such as cancer stem cells (CSCs), may not respond to these therapeutic agents. Accumula…

P63cancer stem cellsCancer ResearchReceptor ErbB-2oncogenesmedicine.medical_treatmentmedicine.disease_causeTargeted therapyERBB3Molecular Targeted TherapyDEATHErbB ReceptorsGene Expression Regulation NeoplasticNeoplastic Stem CellsFemaleOriginal Articlemedicine.drugCARCINOMAMIGRATIONCancer Stem Cells; Breast CancerImmunologyBreast NeoplasmsCancer Stem CellMIR-205miR-205-5pBiologyLapatinibcancer treatmentNOCellular and Molecular Neurosciencebreast cancerBreast cancerErbBCancer stem cellCell Line TumormedicineHumansSUPPRESSIONCell ProliferationMESENCHYMAL TRANSITIONtumorigenesis cancer treatment cancer stem cells miR-205-5p oncogenes breast cancerMICRORNA EXPRESSIONTumor Suppressor ProteinsLapatinibCell BiologyTrastuzumabmedicine.diseaseGENEMicroRNAstumorigenesisDrug Resistance NeoplasmCancer cellQuinazolinesCancer researchNeoplasm Recurrence LocalCarcinogenesisTranscription FactorsCell Death & Disease
researchProduct

INFLAMMATION IN IRRITABLE BOWEL SYNDROME: MYTH OR NEW TREATMENT TARGET?

2016

Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome (IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms u…

Pathologymedicine.medical_specialtyMEDLINEAnti-Inflammatory AgentsInflammationCochrane LibraryBioinformaticsMast cell03 medical and health sciences0302 clinical medicineTreatment targetsGastrointestinal AgentsIntestinal inflammationmedicinePathologyAnimalsHumansMolecular Targeted TherapyTopic HighlightIntestinal MucosaIrritable bowel syndromeInflammationSettore MED/12 - GastroenterologiaMechanism (biology)business.industrySettore BIO/16 - Anatomia UmanaGastroenterologyGeneral MedicineInflammation; Irritable bowel syndrome; Mast cells; Neuroendocrine cells; Pathologymedicine.diseaseEnteritisClinical trialIrritable bowel syndromeSettore MED/18 - Chirurgia Generale030220 oncology & carcinogenesisNeuroendocrine cell030211 gastroenterology & hepatologymedicine.symptomInflammation Mediatorsbusiness
researchProduct

Therapeutic targets for overactive bladder other than smooth muscle

2015

For a long time, our concepts of regulation of urinary bladder function in health and disease as well as of the target structures of therapeutics have focused on detrusor smooth muscle cells. However, other structures including urothelium, afferent nerves and bladder blood vessels may also be important in pathophysiology and its treatment.Based on a selective review of literature, we discuss the role of urothelium, afferent nerve fibers and bladder blood vessels in bladder pathophysiology and as targets for treatment.There is solid evidence now that multiple anatomical structures within the urinary bladder contribute to the regulation of its function and hence may be targets for established…

Pathologymedicine.medical_specialtyMyocytes Smooth MuscleUrinary BladderClinical BiochemistryAnatomical structuresDiseaseurologic and male genital diseasesNerve FibersSmooth muscleAfferentDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyUrotheliumPharmacologyAfferent PathwaysUrinary bladderUrinary Bladder Overactivebusiness.industrymedicine.diseasefemale genital diseases and pregnancy complicationsPathophysiologymedicine.anatomical_structureOveractive bladderDrug DesignMolecular MedicineUrotheliumbusinessNeuroscienceExpert Opinion on Therapeutic Targets
researchProduct

Cinnamomum Species: Bridging Phytochemistry Knowledge, Pharmacological Properties and Toxicological Safety for Health Benefits

2021

The genus Cinnamomum includes a number of plant species largely used as food, food additives and spices for a long time. Different traditional healing systems have used these plants as herbal remedies to cure diverse ailments. The aim of this comprehensive and updated review is to summarize the biodiversity of the genus Cinnamomum, its bioactive compounds, the mechanisms that underlie the pharmacological activities and molecular targets and toxicological safety. All the data in this review have been collected from databases and recent scientific literature including Web of Science, PubMed, ScienceDirect etc. The results showed that the bioactive compounds of Cinnamomum species possess antim…

Pharmacologyclinical trialsPhytochemistryPhytochemistryTraditional medicineWeb of scienceRM1-950ReviewHealth benefitsBiologybiology.organism_classificationmechanisms of actionClinical trialsMechanisms of actionPlant speciesMolecular targetsphytochemistryPharmacology (medical)Toxicological dataTherapeutics. PharmacologyCinnamomumCiannamomum spp.
researchProduct

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

2019

BACKGROUND: Interferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immuneevasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-gamma modulation of PD-L1/PD-L2 in MET-amplified tumours.METHODS: PD-L1/PD-L2 expression and signalling pathways downstream of MET or Interferon-gamma were analysed in MET-amplified tumour cell lines and in patient-derived tumour organoids, in basal condition, upon Interferon-gamma stimulation, and after anti-MET therapy.RESULTS: PD-L1 and PD-L2 were upregulated in MET-amplified tumour cells up…

Programmed cell deathCancer ResearchCancer immunotherapyMET-amplified tumoursB7-H1 AntigenArticleInterferon-gammaTargeted therapiesDownregulation and upregulationInterferonCell Line TumorNeoplasmsHumansMedicineMet inhibitionMolecular Targeted TherapySTAT1Kinase activityReceptorProtein Kinase InhibitorsJanus KinasesReceptors InterferonOncogenebiologyPD-1 ligandsbusiness.industryLiver NeoplasmsOncogenesProto-Oncogene Proteins c-metProgrammed Cell Death 1 Ligand 2 ProteinOrganoidsSTAT1 Transcription FactorOncologybiology.proteinCancer researchOncology; Cancer Research; Met inhibition; IFNγ-induction;PD-1 ligands; MET-amplified tumoursTumor EscapeSignal transductionColorectal NeoplasmsbusinessIFNγ-inductionSignal Transductionmedicine.drug
researchProduct

Neutrophil Extracellular Traps as a Drug Target to Counteract Chronic and Acute Inflammation

2019

Neutrophil extracellular traps (NET), extruded decondensated chromatin entangled with neutrophil proteases, have been first identified in neutrophils stimulated with bacteria or phorbol myristate acetate (PMA) via activation of NADPH oxidase and the generation of reactive oxygen species. Although the first findings demonstrated the beneficial role of NET formation by trapping the bacteria and limiting their dissemination, numerous studies in the recent decade revealed the multifunctional aspects of NET formation which manifests itself not only in the context of anti-microbial effect but also as a pathological trigger. Uncontrolled and exaggerated NET formation or inability to digest and rem…

ProteasesNeutrophilsPharmaceutical ScienceInflammationExtracellular TrapsmedicineHumansMolecular Targeted TherapyInflammationchemistry.chemical_classificationReactive oxygen speciesNADPH oxidasebiologyNADPH OxidasesNeutrophil extracellular trapsChromatinCell biologyHistonechemistryAcute DiseaseChronic Diseasebiology.proteinSignal transductionmedicine.symptomReactive Oxygen SpeciesOxidation-ReductionSignal TransductionBiotechnologyCurrent Pharmaceutical Biotechnology
researchProduct

Multi-output Model with Box-Jenkins Operators of Quadratic Indices for Prediction of Malaria and Cancer Inhibitors Targeting Ubiquitin- Proteasome Pa…

2016

The ubiquitin-proteasome pathway (UPP) is the primary degradation system of short-lived regulatory proteins. Cellular processes such as the cell cycle, signal transduction, gene expression, DNA repair and apoptosis are regulated by this UPP and dysfunctions in this system have important implications in the development of cancer, neurodegenerative, cardiac and other human pathologies. UPP seems also to be very important in the function of eukaryote cells of the human parasites like Plasmodium falciparum, the causal agent of the neglected disease Malaria. Hence, the UPP could be considered as an attractive target for the development of compounds with Anti-Malarial or Anti-cancer properties. R…

Proteasome Endopeptidase ComplexDNA repairDatabases PharmaceuticalAntineoplastic AgentsComputational biologyBioinformatics01 natural sciencesBiochemistryAntimalarialsUbiquitinNeoplasmsDrug DiscoveryHumansMolecular Targeted TherapyMolecular BiologybiologyDrug discoveryUbiquitinComputational BiologyCell BiologyGeneral MedicineCell cyclechEMBL0104 chemical sciencesMalaria010404 medicinal & biomolecular chemistryProteasomeProteolysisbiology.proteinSignal transductionFunction (biology)Current proteinpeptide science
researchProduct